Ansa raises $54.4M Series B led by Cerberus Ventures to expand US DNA manufacturing

Ansa Biotechnologies/Enzymatic long-DNA synthesis

Ansa closed $45.2M with $9.2M more committed, a $54.4M Series B led by Cerberus Ventures, to expand US manufacturing capacity. It also introduced an on-time guarantee: if an order doesn't ship complete and on time, it is free. The company says demand has surged for its clonal DNA up to 50 kb.

• New investors: Fall Line Capital, AIM13, Black Opal Ventures.
• Products: sequence-perfect clonal DNA and sequence-verified linear fragments.
• All manufacturing in the United States.